Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of subcutaneous garadacimab for prophylaxis of hereditary angioedema attacks in adolescents
MOH_2021-01-10_009467Phase 3Not yet recruiting
- Sponsor
- CSL Behring
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hereditary angioedema (HAE) comparing Garadacimab with Placebo (2 arms). Planned start Dec 2020; status: not yet recruiting.
02
Drugs
garadacimab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on MOH_2021-01-10_009467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-10_009467.